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Interaction between cell surface receptors that contain tyrosine kinase activity and their cognate ligands is one of the
fundamental mechanisms by which metazoan cells communicate. Generally, ligand binding to receptor tyrosine kinases
induces dimerization or oligomerization of receptor monomers,
which leads to activation and potentiation of their intrinsic
catalytic activity and phosphorylation of tyrosine residues.
These phosphotyrosines serve as binding sites for cytoplasmic
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served throughout evolution and includes a set of invariant
amino acid residues and consensus motifs that participate in
the phosphotransfer reaction (2, 3).
Through the identification of novel receptor tyrosine kinases,
it has become apparent that some receptor tyrosine kinases
have diverged to incorporate alterations in conserved amino
acid residues in the kinase domain and to function as signaltransducing molecules that lack catalytic activity. These include ErbB3 (4 – 6), the Ryk subfamily (Ryk, Derailed, and
Doughnut) (7–10), and the CCK-4 (colon carcinoma kinase-4)
subfamily (CCK-4/PTK7 (protein tyrosine kinase 7), Klg, Dtrk,
and Lemon) (11–15). Despite the lack of kinase activity, these
molecules can transduce extracellular signals across the
plasma membrane and mediate biological functions. The beststudied example is the ErbB3 receptor of the epidermal growth
factor receptor family, which plays crucial roles in development
by heterodimerizing with kinase-active ErbB receptors and
then modulating their ligand affinities and functions (1). More
recently, it has been reported that a targeted gene disruption of
Ryk in mouse causes cleft palate (16). In Drosophila, the homolog of Ryk, Derailed, acts as a repulsive axon guidance receptor by interacting with Wnt5 (17, 18). These findings indicate
that kinase-defective receptor molecules have been conserved
in evolution and play crucial roles in signaling for normal
development.
Eph receptors form the largest known subfamily of receptor
tyrosine kinases, and to date, the Eph subfamily contains 16
members in vertebrates (19, 20) (see Eph nomenclature web
site (cbweb.med.harvard.edu/eph-nomenclature/) for update).
The Eph receptors interact with a family of ligands, ephrins.
All the ephrins are membrane-attached, either via a glycosylphosphatidylinositol anchor (ephrin-A1–A6) or a transmembrane domain (ephrin-B1–B3). The Eph receptors are also
grouped into two classes, EphA receptors (EphA1–A10) and
EphB receptors (EphB1–B6). These groupings roughly correspond to the receptor-ligand interaction (i.e. ephrin-As show
binding preference for EphA receptors, and ephrin-Bs for EphB
receptors), although there is a wide variation in affinity within
each group, and some interactions cross the group boundary.
Eph receptors and ephrins have been implicated in many developmental processes, including axon guidance, synaptogenesis, embryonic compartmentation, and vascular development
(21–24). The Eph-ephrin interaction has also been shown to
regulate cell adhesion and migration. Although in most cases
the Eph-ephrin interaction exerts repulsive or inhibitory functions, ephrins have been reported to have attractive or adhesive effects in several biological systems (25–27). However, the
molecular mechanisms by which they can mediate differential
functions remain to be elucidated.
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EphB6 is a unique member in the Eph family of receptor tyrosine kinases in that its kinase domain contains
several alterations in conserved amino acids and is catalytically inactive. Although EphB6 is expressed both in
a variety of embryonic and adult tissues, biological functions of this receptor are largely unknown. In the present study, we examined the function of EphB6 in cell
adhesion and migration. We demonstrated that EphB6
exerted biphasic effects in response to different concentrations of the ephrin-B2 ligand; EphB6 promoted cell
adhesion and migration when stimulated with low concentrations of ephrin-B2, whereas it induced repulsion
and inhibited migration upon stimulation with high
concentrations of ephrin-B2. A truncated EphB6 receptor lacking the cytoplasmic domain showed monophasic-positive effects on cell adhesion and migration, indicating that the cytoplasmic domain is essential for the
negative effects. EphB6 is constitutively associated with
the Src family kinase Fyn. High concentrations of ephrin-B2 induced tyrosine phosphorylation of EphB6
through an Src family kinase activity. These results indicate that EphB6 can both positively and negatively
regulate cell adhesion and migration, and suggest that
tyrosine phosphorylation of the receptor by an Src family kinase acts as the molecular switch for the functional
transition.
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EXPERIMENTAL PROCEDURES

Expression Constructs—The coding region of human EphB6 cDNA
(nucleotide numbers 754 –3819, GenBankTM accession number D83492
(29)) was subcloned into the pcDNA3.1 expression vector (Invitrogen)
(pcDNA-EphB6). To express a truncated form of EphB6 (EphB6⌬C), the
sequence that corresponds to most of the intracellular domain (amino
acids 625–1021 (29)) was deleted and replaced with a termination codon
and was subcloned into pcDNA3.1 (pcDNA-EphB6⌬C).
Cell Culture and Transfection—Human embryonic kidney (HEK)1
293T cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum
(Life Technologies, Inc.). To establish cell lines that stably express the
full-length or a truncated EphB6 receptor, cells were transfected with
EphB6 expression constructs (pcDNA-EphB6 or pcDNA-EphB6⌬C) using FuGENE transfection reagent (Roche Applied Science) and cultured
in the presence of 1 mg/ml G418 (Sigma). G418-resistant clones were
isolated by limited dilution and expanded. Multiple clones that show
high expression of the receptors were established for each construct and
used in the experiments described here. Establishment and maintenance of Chinese hamster ovary (CHO) cell clones that express EphB6
(CHO-HEP cells) have been previously described (35).
Affinity Probe in Situ—Affinity probe in situ was performed as previously described (36). Briefly, unfixed cells were incubated with ephrin-B2-AP or AP for 30 min at room temperature. After washing, cells
were briefly fixed with 8% formaldehyde (3 min), washed, and heated
for 60 min at 65 °C to inactivate endogenous APs. Ligand binding was
detected by incubation with 5-bromo-4-chloro-3-indolyl phosphate/5bromo-4-chloro-3-indolyl phosphate.
Cell Adhesion Assays—Twenty-four-well plates were coated with
1
The abbreviations used are: HEK, human embryonic kidney; AP,
alkaline phosphatase; BSA, bovine serum albumin; CHO, Chinese hamster ovary; DMEM, Dulbecco’s modified Eagle’s medium; PBS, phosphate-buffered saline; PDZ, PSD95/Dlg/ZO-1; PTB, protein tyrosinebinding; SH2, Src homology 2; SHIP-1, Src homology 2 domaincontaining tyrosine phosphatase-1; PP2, 4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazolo[3,4-D]pyrimidine; PP3, 4-amino-7-phenylpyrazol[3,4-D]pyrimidine.

serial dilutions of ephrin-B2-Fc or Fc in phosphate-buffered saline
(PBS) containing 5 mg/ml bovine serum albumin (BSA) at 4 °C overnight, incubated with 2% BSA in PBS for 60 min, and then washed with
DMEM. Cells were detached non-enzymatically with Cell Dissociation
Solution (Sigma), washed twice with DMEM, and plated in triplicate
onto wells in DMEM at 2 ⫻ 105 cells per well. Cells were then allowed
to adhere for 30 min at 37 °C. For quantification, non-adhering cells
were washed away, and the remaining adhering cells were fixed with
4% paraformaldehyde and stained with 0.5% crystal violet in 10%
methanol. The cells were then lysed and quantified. For observation of
cell morphology, 1 ⫻ 105 cells per well were plated and cultured in
DMEM containing 1% fetal bovine serum at 37 °C for 48 h.
Cell Migration Assays—For the transfilter migration assay, the
lower side of filter inserts (8-m pore size, Transwell, Corning Inc.) was
coated with different concentrations of ephrin-B2-Fc or Fc (R&D systems) in PBS containing 5 mg/ml BSA at 4 °C overnight, blocked with
2% BSA at room temperature for 60 min, and then washed with DMEM.
1 ⫻ 105 cells were placed in the top chamber, and allowed to migrate to
the underside of the filter overnight in DMEM containing 1% fetal
bovine serum at 37 °C. The cells were then fixed with 4% paraformaldehyde and stained with 0.5% crystal violet in 10% methanol. After
washing with water, the upper side of the filter was gently wiped, and
the cells migrated and attached to the lower side were quantified and
photographed. Each condition was tested in triplicate per experiment,
and each experiment was repeated 3–5 times with consistent results.
Immunoprecipitation and Immunoblot Analysis—Cells were lysed in
cold lysis buffer (50 mM HEPES (pH 7.4), 50 mM NaCl, 1% Triton X-100,
5 mM EDTA, 1⫻ protease inhibitors mixture (Sigma), 2 mM sodium
vanadate, 25 mM sodium fluoride). After 15 min of incubation on ice, the
cell lysates were centrifuged for 30 min at 15,000 ⫻ g to remove
insoluble material. The lysates were pre-cleared by incubating with
50% slurry protein G-Sepharose (Amersham Biosciences) for 30 min at
4 °C. Primary antibody (anti-EphB6 antibody (R&D Systems) or antipan-Src antibody (Santa Cruz Biotechnology)) was incubated with 50%
protein G-Sepharose in PBS for 2 h at 4 °C. The antibody-protein
G-Sepharose complex was then washed and mixed with the pre-cleared
lysates and incubated for 2 h at 4 °C with rotation. The immunocomplexes were pelleted by centrifugation, washed five times, and boiled for
3 min in Laemmli sample buffer. The lysates were then separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE, 7.5% or 10% polyacrylamide gel). After transfer of the proteins onto polyvinylidene fluoride membrane, the filters were blocked with 5% skim milk in PBS
containing 0.05% Tween 20, and treated with anti-EphB6 antibody
(Santa Cruz Biotechnology, 1 g/ml), or anti-pan-Src antibody (Santa
Cruz Biotechnology, 0.2 g/ml). For treatment with anti-Fyn antibody
and the anti-phosphotyrosine antibody 4G10, the filters were blocked
with 5% BSA, 0.05% Tween 20 in Tris-buffered saline. Detection was
performed using the ECL Plus system (Amersham Biosciences). For
inhibition of Src family kinases, cells were serum-starved for 20 h and
pretreated with PP2, PP3 (Calbiochem) or Me2SO for 1 h, and then
incubated in the culture medium containing ephrin-B2-Fc (12.5 g/ml)
for 30 min.
RESULTS

Stable Expression of EphB6 in HEK293T Cells—To investigate the function of EphB6 in cellular behavior, we established
HEK293T cells that stably express the full-length human
EphB6 cDNA (HEK-EphB6 cells). High expression of EphB6
was detected by immunoblotting using antibody against the
extracellular domain of EphB6 (Fig. 1A). HEK293T cells transfected with the pcDNA3.1 vector did not express detectable
levels of EphB6 (Fig. 1A). In the studies described below, several independent clones that express a high level of EphB6
protein were used, and similar results were obtained.
We first tested whether the EphB6 receptor expressed on
HEK293T cells could interact with a cognate ligand. Although
the Eph-ephrin interaction generally shows a high degree of
promiscuity, ephrin-B2 has been shown to be the major ligand
that binds to EphB6 with a significant affinity (37). We therefore performed a ligand-binding assay using the extracellular
domain of ephrin-B2 fused to an alkaline phosphatase (AP) tag
(ephrin-B2-AP) as a probe (affinity probe in situ) (36). Strong
binding was observed on the surface of HEK-EphB6 cells (Fig.
1B), whereas neither parental HEK293T cells (data not shown)
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EphB6 was identified in efforts to clone novel receptor
tyrosine kinases in mouse (28) and in human (29), by a
PCR-based screening and a low stringency library screening,
respectively. Although the extracellular region of the EphB6
receptor shares all the structural features of other Eph family members, the cytoplasmic “kinase domain” has several
critical amino acid substitutions and fails to show catalytic
activity in vitro (28, 29). EphB6 is highly expressed in the
developing and adult nervous system and thymus and is
expressed at low levels in other tissues, including heart,
kidney, and liver. Several reports have demonstrated that
EphB6 transduces signals and plays roles in T cell functions
(30 –34), but its biological functions in cellular behavior are
still largely unknown. In the present study, we examined
functions of EphB6 in cell adhesion and migration. We demonstrate that, upon stimulation with ephrin-B2, the kinasedefective EphB6 receptor exerts biphasic functions: EphB6
promotes cell adhesion and migration in response to low
concentrations of ephrin-B2, whereas EphB6 induces repulsion and suppresses migration when stimulated with high
concentrations of ephrin-B2. The cytoplasmic domain is essential for repulsion and inhibition of migration, because a
truncated EphB6 that lacks the cytoplasmic domain promotes cell adhesion and migration in monophasic and dosedependent manners. In addition, when exposed to high concentrations of ephrin-B2, EphB6 is tyrosine phosphorylated
by an Src family kinase, which constitutively associates with
the receptor. Our results indicate that the kinase-defective
EphB6 receptor can regulate cell adhesion and migration by
exerting both positive and negative effects and suggest that
tyrosine phosphorylation of the receptor may act as a switch
on the functional transition from adhesion/attraction to
de-adhesion/repulsion.

Functional Transition of EphB6 in Cell Adhesion/Migration
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FIG. 1. Expression and ligand binding activity of the EphB6 receptor in
HEK-EphB6
cells.
Representative
clones of HEK-EphB6 cells were tested for
EphB6 protein expression and ephrin-B2
ligand binding activity. A, immunoblot
(IB) analysis of EphB6 expression in
HEK-EphB6 cells and vector-transfected
HEK293T cells (HEK-vector). Strong expression of EphB6 was detected in HEKEphB6 cells, but not in vector-transfected
HEK293T cells. B, ligand binding activity
detected by affinity probe in situ. HEKEphB6 cells and vector-transfected
HEK293T cells were treated with ephrinB2-AP or AP. Dark staining represents
the positive signal. HEK-EphB6 cells
show specific ligand binding activity on
their cell surface.

showed no morphological changes. Ephrin-B2-Fc did not affect
the rate of cell proliferation or cell death (data not shown). These
results indicate that the EphB6 receptor exerts dual functions
that lead to either cell adhesion/spreading or repulsion/rounding, depending on the ligand concentrations.
Biphasic Effects of Ephrin-B2 on Migration of HEK-EphB6
Cells—Because many signaling molecules regulating cell adhesion are also involved in cell migration, we next examined if
ephrin-B2 affects migration of HEK-EphB6 cells. To test this,
we set up a transfilter assay system, in which a membrane with
defined uniform pore size separates upper and lower chambers.
The lower side of porous membrane was coated with different
concentrations of ephrin-B2-Fc or Fc. HEK-EphB6 cells were
then plated in the upper chamber and allowed to migrate to the
lower side of the filter overnight.
When the porous membrane was coated with different concentrations of ephrin-B2-Fc, HEK-EphB6 showed a biphasic
behavior in cell migration (Fig. 3, A and B). In response to low
concentrations (0.04 –1.0 g/ml) of ephrin-B2-Fc, migration of
HEK-EphB6 cells was stimulated in a dose-dependent manner.
In contrast, when the cells were tested with high concentrations (5.0 –12.5 g/ml) of ephrin-B2-Fc, cell migration was significantly reduced. Remarkably, at 12.5 g/ml ephrin-B2-Fc,
fewer HEK-EphB6 cells migrated to the lower side of membrane compared with the control, indicating that ephrin-B2
inhibits HEK-EphB6 cell migration at this concentration. The
Fc-coated membranes exerted no obvious effects on HEKEphB6 cell migration, and migration of control HEK293T cells
transfected with the pcDNA3.1 vector was not affected by ephrin-B2-Fc or Fc (Fig. 3B). Similar results were obtained in
experiments in which the membranes were coated with preclustered ephrin-B2-Fc (data not shown).
To investigate whether the effects of ephrin-B2-Fc on cell
migration are dependent on cell types, we tested CHO cell lines
that stably express EphB6 (CHO-HEP cells) (35) in this cell
migration assay. As observed in HEK-EphB6 cells, migration of
CHO-HEP cells was stimulated by lower concentrations of ephrin-B2-Fc, and inhibited by higher concentrations of ephrinB2-Fc (Fig. 3C). These results indicate that the biphasic effect
in cell migration represents a global function of EphB6 and is
not restricted to a small subset of cell types.
The biphasic response of HEK-EphB6 cells and CHO-HEP
cells in the cell migration assay was consistent with the results
of cell adhesion assay described above. Moreover, the ephrin-B2 concentrations at which the transition of effects (promotion to inhibition) was observed were comparable between the
two assays (i.e. between 1 and 5 g/ml).
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nor vector-transfected HEK293T cells (Fig. 1B) showed detectable binding activity. Control AP did not bind to either HEKEphB6 cells or vector-transfected HEK293T cells (Fig. 1B).
These results confirmed that in HEK-EphB6 cells the EphB6
receptor is expressed on cell surface and can interact with
ephrin-B2.
Immobilized Ephrin-B2 Exerts Dual Effects on HEK-EphB6
Cell Adhesion and Morphology—Previous studies have shown
that interactions between kinase-active Eph receptors and
ephrins can regulate cell adhesion (25, 27, 38 – 41). Because
EphB6 is catalytically inactive, we examined whether this receptor also has the ability to modulate cell adhesion.
HEK-EphB6 cells were plated onto a substratum coated with
different concentrations of ephrin-B2-Fc, and cell adhesion to
substratum was measured 30 min later. As shown in Fig. 2A,
HEK-EphB6 cells showed enhanced adhesion to the substratum coated with low concentrations of ephrin-B2-Fc. A dosedependent promotion of cell adhesion was observed between
0.04 and 1.0 g/ml ephrin-B2-Fc. When the ligand concentration was further increased (5.0 –12.5 g/ml), however, adhesion
of HEK-EphB6 cells decreased to background levels. Immobilized Fc showed no effects on adhesion of HEK-EphB6 cells.
Adhesion of vector-transfected control cells was not significantly affected by the ephrin-B2-Fc-containing substratum. In
a separate set of experiments, ephrin-B2-Fc was pre-clustered
with anti-human IgG-Fc and used for the assay. Pre-clustered
ephrin-B2-Fc showed similar dual effects on adhesion of HEKEphB6 cells (data not shown).
This cell adhesion assay was performed under stringent
conditions, in which the wells were pre-coated (blocked) with
a high concentration of BSA, and the cells were allowed to
attach to substratum for 30 min, so there was essentially no
basal level of cell adhesion. We therefore could not determine
whether high concentrations of ephrin-B2 in fact actively
induced repulsion of HEK-EphB6 cells, or had no effect on
cell adhesion. To verify this, HEK-EphB6 cells were incubated on ephrin-B2-Fc-coated substratum for 48 h, and the
morphology of cells was observed (Fig. 2B). When the substratum was coated with 0.2 g/ml ephrin-B2, HEK-EphB6
cells showed a slight spreading morphology compared with
the cells on the control substratum. In contrast, the substratum coated with higher concentrations of ephrin-B2 caused
dramatic changes to cell morphology; the cells became
rounded and formed aggregates that protruded from the substratum, indicating that high concentrations of ephrin-B2
induced cell repulsion and de-adhesion from the substratum.
Control cells plated on ephrin-B2-Fc-coated substratum

29358

Functional Transition of EphB6 in Cell Adhesion/Migration

FIG. 3. Biphasic effects of EphB6 on
transfilter cell migration. HEK-EphB6
cells (A and B) or CHO-HEP cells (C) were
placed in the upper chamber of a Transwell apparatus, in which the lower side
of filter was coated with different concentrations of ephrin-B2-Fc or Fc, and the
cells were allowed to migrate to the lower
side at 37 °C overnight. Vector-transfected cells were used as controls. The
cells that had migrated to the lower side
of filter were stained, photographed (A),
and quantified (B and C). Control migration to BSA-coated filters is shown as 0.
Migration of HEK-EphB6 cells and CHOHEP cells was stimulated by low concentrations of eprhin-B2-Fc, but inhibited by
higher concentrations of ephrin-B2-Fc.

A Truncated EphB6 Receptor Exerts Monophasic Stimulatory Effects on Cell Adhesion and Migration—The results of the
cell adhesion and migration assays suggest that EphB6 mediates two types of signaling (adhesion/attraction and de-adhesion/repulsion) in response to different concentrations of eph-

rin-B2. Because the EphB6 receptor is devoid of tyrosine kinase
activity, we were next interested in whether the cytoplasmic
domain of EphB6 is essential for mediating signals for the
biphasic responses in cell adhesion/migration. To test this, we
constructed a truncated form of EphB6 that lacks most of the
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FIG. 2. Dual functions of EphB6 in cell adhesion to ephrin-B2-containing substratum. HEK-EphB6 cells and vector-transfected
HEK293T cells were plated onto substratum coated with different concentrations of ephrin-B2-Fc or Fc. A, cell adhesion after 30-min incubation.
Adhesion efficiencies after subtracting the control adhesion (to BSA) are presented. Values represent means ⫾ S.E. B, cell morphology of
HEK-EphB6 cells and vector-transfected HEK293T cells after 48 h incubation on substratum coated with BSA or different concentrations of
ephrin-B2-Fc. HEK-EphB6 cells showed well spread morphology on low concentrations of ephrin-B2-Fc, whereas high concentrations of ephrinB2-Fc induced cell rounding and detachment from the substratum.
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FIG. 4. Expression and ligand binding activity of a truncated EphB6 receptor in HEK-EphB6⌬C cells. A, expression of a truncated EphB6 receptor
(EphB6⌬C) in HEK-EphB6⌬C cells detected by immunoblot analysis. B, ligand
binding activity of EphB6⌬C (dark staining) detected by affinity probe in situ using ephrin-B2-AP.

hanced cell adhesion and migration of HEK-EphB6 cells. In
contrast, incubation with high concentrations of ephrin-B2,
which led to inhibition of cell adhesion/migration, resulted in
significant tyrosine phosphorylation of the receptor. High concentrations of control Fc substratum had no effects. Tyrosine
phosphorylation of EphB6 was confirmed in experiments in
which immunoprecipitation with anti-phosphotyrosine antibody was followed by immunoblotting with anti-EphB6 antibody (Fig. 6B). Similar results were obtained when HEKEphB6 cells were stimulated by soluble ephrin-B2-Fc (Fig. 6C).
An Src Family Kinase Constitutively Associates with and
Tyrosine Phosphorylates EphB6 —Because the kinase domain
of EphB6 is catalytically inactive, the tyrosine phosphorylation
of EphB6 observed above must be mediated by a separate
tyrosine kinase. Interestingly, when HEK-EphB6 cells were
treated with high concentrations of ephrin-B2-Fc, tyrosine
phosphorylation of a 60-kDa protein that was co-immunoprecipitated with EphB6 was also induced (Fig. 6A). Because
members of the Src family tyrosine kinases have similar molecular weights (42, 44, 45), we tested whether this protein is
an Src family member. We treated HEK-EphB6 cells with
different concentrations of ephrin-B2-Fc, and performed immunoprecipitation with anti-EphB6 antibody followed by immunoblotting with anti-pan-Src antibody or antibodies against
specific Src family members. As shown in Fig. 7A, the 60-kDa
protein could be detected with anti-pan-Src antibody. In addition, anti-Fyn antibody specifically recognized the 60-kDa protein. Intriguingly, although its tyrosine phosphorylation was
significantly induced by stimulation with high concentrations
of ephrin-B2, amounts of Fyn co-immunoprecipitated with
EphB6 did not change by ligand treatments, indicating that
Fyn associates with EphB6 both in the absence and presence
(low and high concentrations) of ligand.
To confirm that an Src family kinase is tyrosine phosphorylated in response to high concentrations of ephrin-B2, HEKEphB6 cells were treated with ephrin-B2-Fc, and cell lysates
were immunoprecipitated with anti-pan-Src antibody and immunoblotted with anti-phosphotyrosine antibody (Fig. 7, A and
B). As expected, robust tyrosine phosphorylation was detected
by high concentrations of ephrin-B2. In contrast, when lysates
of HEK-EphB6⌬C cells were tested, tyrosine phosphorylation
was not detectable (Fig. 7B), indicating that the cytoplasmic
domain of EphB6 is essential for the ephrin-B2-induced tyrosine phosphorylation of Src family kinases.
Finally, we examined whether EphB6 phosphorylation is
mediated by an Src family kinase. HEK-EphB6 cells were
pretreated with the Src inhibitor, PP2, and then tested for

Downloaded from www.jbc.org at Aberdeen University on January 31, 2007

cytoplasmic domain (EphB6⌬C). The cytoplasmic region of
EphB6⌬C has only four amino acids and lacks all the known
signaling motifs conserved among the Eph receptors, including
the two juxtamembrane tyrosine residues that are the major
autophosphorylation sites in kinase-active Eph receptors (42–
44). HEK293T cells were stably transfected with an EphB6⌬C
expression construct, and several independent clones were established (HEK-EphB6⌬C cells). As in HEK-EphB6 clones,
expression and ligand binding activity of the truncated receptor were confirmed by immunoblotting and affinity probe in
situ using ephrin-B2-AP, respectively (Fig. 4).
HEK-EphB6⌬C cells were then tested for adhesion activity
to ephrin-B2-coated substratum (Fig. 5A). At all concentrations
of ephrin-B2 used in the assay, HEK-EphB6⌬C cells always
showed a dose-dependent enhancement in cell adhesion. In
striking contrast to HEK-EphB6 cells, cell adhesion of HEKEphB6⌬C was not inhibited by high concentrations of ephrinB2. After 48-h incubation, HEK-EphB6⌬C cells showed a
spreading morphology not only at low concentrations, but also
at high concentrations of ephrin-B2-Fc (Fig. 5B). Consistent
with these results, in the transfilter assay, HEK-EphB6⌬C
cells showed a monophasic and dose-dependent promotion of
migration in response to ephrin-B2-Fc (Fig. 5, C and D), and
inhibition of cell migration at high concentrations of ephrinB2-Fc was not observed. The degree of cell migration induced
by low concentrations of ephrin-B2-Fc was slightly lower than
that observed for HEK-EphB6 cells, suggesting that the cytoplasmic domain may also be involved in signaling for stimulation of cell migration. These results indicate that the extracellular domain of EphB6 is capable of promoting cell adhesion
and migration in response to low concentrations of ephrin-B2,
but the cytoplasmic domain is essential for cell repulsion and
inhibition of migration induced by high concentrations of
ephrin-B2.
EphB6 Is Tyrosine-phosphorylated by High Concentrations of
Ephrin-B2—Previous studies have shown that EphB6 can be
phosphorylated on its tyrosine residues by ligand stimulation
(30). Because EphB6 can exert both positive and negative effects on cell adhesion and migration, we next investigated how
tyrosine phosphorylation of EphB6 related to the biphasic cellular behavior. To test this, HEK-EphB6 cells were plated onto
substratum coated with different concentrations of ephrinB2-Fc and incubated for 60 min at 37 °C. The EphB6 receptor
was then immunoprecipitated with anti-EphB6 antibody and
immunoblotted with anti-phosphotyrosine antibody (Fig. 6A).
Tyrosine phosphorylation of EphB6 was not detectable by stimulation with low concentrations of ephrin-B2-Fc, which en-
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FIG. 6. Tyrosine phosphorylation of
EphB6 induced by high concentrations of ephrin-B2. A and B, HEKEphB6 cells were plated onto the substratum coated with different concentrations
of ephrin-B2-Fc or Fc, incubated for 60
min, and then lysed. A, the cells were
immunoprecipitated (IP) with antiEphB6 antibody, and immunoblotted (IB)
with anti-phosphotyrosine (p-Tyr) antibody. Tyrosine phosphorylation of EphB6
can be detected when the cells were
treated with high concentrations of ephrin-B2-Fc. A 60-kDa protein (p60) is also
tyrosine-phosphorylated and co-immunoprecipitated with EphB6. B, the cells
were immunoprecipitated with anti-phosphotyrosine antibody, and then immunoblotted with anti-EphB6 antibody. C,
HEK-EphB6 cells were stimulated with
soluble ephrin-B2-Fc and treated as in A.

tyrosine phosphorylation by stimulation with high concentration of ephrin-B2. PP2, but not a control, PP3, or Me2SO,
inhibited tyrosine phosphorylation of both EphB6 and an Src
family kinase (Fig. 7C). Taken together, these results indicate
that Fyn constitutively associates with EphB6 in a ligandindependent manner and that stimulation with high concentrations of ephrin-B2 induces tyrosine phosphorylation and
activation of an Src family kinase, which in turn phosphorylates EphB6.
DISCUSSION

Biphasic Functions of the Kinase-defective EphB6 Receptor
and Functional Transition from Promotion to Inhibition—Although “kinase-active” Eph receptors have been shown to play

important roles in cell adhesion and migration both in vitro (25,
27, 38 – 41, 46 –50) and in vivo (51–54), little is known about the
functions and signaling mechanisms of the kinase-defective
EphB6 receptor in cellular behavior. In the present study, we
have demonstrated that the EphB6-ephrin-B2 interaction directly regulates cell adhesion and migration and that, despite
its catalytically defective kinase domain, EphB6 retains the
ability to mediate signaling that controls cellular behavior.
Our results have also shown that EphB6 exerts biphasic
functions in adhesion and migration in response to different
concentration of ligand, with a functional transition from promotion to inhibition. Although Eph receptors were initially
described to mediate repulsive signals in growing axons, it has
become clear that they have functional versatility, including
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FIG. 5. Monophasic promoting effects of EphB6⌬C on cell adhesion
and migration. A and B, cell adhesion
assay. HEK-EphB6⌬C cells were plated
onto substratum coated with different
concentrations of ephrin-B2-Fc or Fc. A,
quantification of HEK-EphB6⌬C cell adhesion after 30-min incubation. Ephrin-B2-Fc
promoted adhesion of HEK-EphB6⌬C cells
in a dose-dependent manner. B, morphology of HEK-EphB6⌬C cells after 48-h
incubation on substratum coated with BSA
or different concentrations of ephrin-B2-Fc.
HEK-EphB6⌬C cells showed well spread
morphology both on low and high concentrations of ephrin-B2-Fc. C and D, cell migration assay. HEK-EphB6⌬C cells were
tested in the transfilter migration assay as
in Fig. 3. Migration of HEK-EphB6⌬C cells
was stimulated by ephrin-B2-Fc. Note that
in both cell adhesion and migration assays,
inhibitory effects by high concentrations of
ephrin-B2-Fc were not observed.
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adhesive and attractive functions. For example, it has been
previously reported that ephrin-B ligands act as bifunctional
guidance cues for migrating trunk neural crest cells in vivo;
they repel early neural crest cells that migrate through the
ventrolateral pathway, and later stimulate the migration of
melanoblasts into the dorsolateral pathway (54). In addition, in
the developing visual system, ephrin-Bs have been shown to act
as both attractants and repellents to retinal axons (55–57).
Whereas in vivo studies have suggested that a transition from
attraction to repulsion mediated by the EphB-ephrin-B interaction is involved in the establishment of topographic retinal
axon mapping (57), such functional transition has not been
directly shown for EphB receptors. Our results therefore represent the first demonstration that an EphB receptor can exert
a promotion-to-inhibition transition in regulation of cellular
behavior. Interestingly, it has recently been demonstrated in
an in vitro axon outgrowth assay that in response to ephrin-As,
retinal axons show a graded, concentration-dependent transition from growth promotion to inhibition (58). Together with
the results in the present studies, these findings suggest that
biphasic action may be a common feature of Eph receptor
functions, shared by both EphA and EphB receptors, and by
both kinase-active and kinase-defective receptors. Although its
in vivo functions in cell adhesion and migration have not been
identified, EphB6 is expressed in various tissues both during
development and in the adult (28, 29, 35). It is particularly
intriguing that EphB6 is expressed in the ganglionic eminence,
a source of tangentially migrating neurons and glial cells into
the cerebral cortex,2 raising the possibility that EphB6 may act
as a guidance receptor in neuronal migration.
Whereas the molecular mechanism that regulates the transition from promotion to inhibition has not been elucidated,
multiple factors could be involved in determining the final
output of cell behavior, including the status of receptor multimerization, profiles of phosphorylation in the cytoplasmic
2

H. Matsuoka and M. Nakamoto, unpublished observation.

domain, and combinations of signaling molecules recruited to
the receptor. Although not directly addressed in the present
study, our results suggest that in the case of EphB6, tyrosine
phosphorylation of the receptor acts as a switch of the transition in cell behavior mediated by the receptor-ligand interaction. This concept is consistent with the previous studies demonstrating that kinase-active Eph receptors can promote cell
adhesion in kinase-independent manners. For example, although interaction between cells expressing EphA7 and ephrin-A5 resulted in cell repulsion, co-expression of a truncated
form of EphA7 that lacks the tyrosine kinase domain suppresses tyrosine phosphorylation of the full-length receptor and
shifts the cellular response from repulsion to adhesion (27).
Another study has shown that EphA8 promotes integrin-mediated cell attachment in a tyrosine kinase activity-independent
fashion (47). These findings suggest that adhesive/attractive
functions of Eph receptors can be exerted by tyrosine kinaseindependent signaling, whereas repulsive functions require tyrosine kinase activity and receptor phosphorylation. It should
be emphasized, however, that adhesion/attraction does not always equal kinase-independent signaling, because EphB1-mediated cell attachment to fibronectin is kinase-dependent (46).
Signaling through the Kinase-defective EphB6 Receptor—
Regarding the signaling mechanism through the EphB6 receptor, several different, but not mutually exclusive, possibilities
could be considered. First, the EphB6 receptor may form a
hetero-dimer or a hetero-oligomer with catalytically active Eph
receptors, by analogy with the catalytically inactive ErbB3
receptor of the epidermal growth factor receptor subfamily (59).
It was recently demonstrated that EphB6 can associate with
and be transphosphorylated by EphB1, if the both receptors are
overexpressed in the same cells (30). Although it remains to be
determined whether such hetero-receptor complexes are
formed and function in vivo, those findings raise the interesting
possibility that EphB6 may modulate the signaling and function of catalytically active Eph receptors. In our system, however, it does not seem likely that this mechanism plays the
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FIG. 7. A Src family kinase induces tyrosine phosphorylation of EphB6 in response to high concentrations of ephrin-B2. A,
HEK-EphB6 cells were treated with different concentrations of ephrin-B2-Fc or Fc, and were subjected to immunoprecipitation (IP) followed by
immunoblotting (IB) as indicated. All bands shown here represent the 60-kDa protein in Fig. 6A. The Src family kinase Fyn constitutively
associated with EphB6. High concentrations of ephrin-B2-Fc induced tyrosine phosphorylation of Fyn. B, HEK-EphB6 and HEK-EphB6⌬C cells
were stimulated with a high concentration (12.5 g/ml) of ephrin-B2-Fc, and tyrosine phosphorylation of Src family kinases was evaluated.
Tyrosine phosphorylation was induced in HEK-EphB6 cells, but not in HEK-EphB6⌬C cells. C, HEK-EphB6 cells were pretreated with PP2, PP3,
or Me2SO (DMSO) and then stimulated with a high concentration of ephrin-B2-Fc. The cells were then tested for tyrosine phosphorylation of
EphB6 and the 60-kDa protein. PP2 significantly reduces tyrosine phosphorylation of the both molecules.
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present throughout most of metazoan existence. This raises the
intriguing question of why the kinase-defective receptors,
which are likely to have been generated by inactivating mutations following gene duplication (67), have been positively selected in metazoan evolution. A plausible explanation would be
that by forming a complex with kinase-dead receptors, receptor
tyrosine kinases could modify their ligand affinity/specificity
and signaling pathway, and thus obtain more functional diversity. Another possibility would be that, by separating the kinase activity from the receptor, tyrosine phosphorylation of
receptors could be more precisely controlled. Usually, receptor
phosphorylation is triggered by receptor dimerization/oligomerization, and its regulation is largely dependent on ligandreceptor interaction (e.g. ligand concentration, receptor distribution on the cell surface, and ligand-receptor affinity). If
receptor phosphorylation is mediated by an independent kinase (e.g. Src family kinases), it would become possible to
control the phosphorylation after the receptor-ligand interaction occurs. These functional flexibilities are likely to have been
advantageous for metazoan organisms to properly respond to
environmental changes.
At present, kinase-defective Eph receptors have been identified only in mammals (human and mouse). As more metazoan
genomes are sequenced, it will be intriguing to see if orthologs
of EphB6 or other kinase-defective Eph receptors exist in lower
vertebrates and/or invertebrates. It will also be of great interest to determine what additional signaling pathways and functions the EphB6 receptor has obtained by inactivating its intrinsic kinase. Clearly, the Eph family will act as a good model
to study the function of catalytically-defective receptor tyrosine
kinases in relation to their catalytically active counterparts.
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main role in the regulation of cell adhesion and migration,
because ephrin-B2-AP did not show detectable binding to the
parental HEK293T cells used in our experiments (Fig. 1B).
Second, the cytoplasmic domain of EphB6 may recruit a
specific set of signaling molecules and mediate intracellular
signaling in an intrinsic kinase activity-independent manner.
Although we showed that a truncated EphB6 receptor that
lacks the cytoplasmic domain can promote cell adhesion and
migration, our results do not rule out the possibility that the
cytoplasmic domain of EphB6 can transduce signals for stimulation of cell adhesion and migration. Interestingly, the degree of cell migration induced by low concentrations of ephrin-B2 is slightly higher in HEK-EphB6 cells than in HEKEphB6⌬C cells (Figs. 3 (A and B) and 5 (C and D)). Because the
full-length and truncated EphB6 receptors are expressed at
comparable levels in these cell lines, this may suggest that the
cytoplasmic domain of the receptor transduces signals in stimulation of cell migration. Remarkably, the cytoplasmic domain
of EphB6 retains all the known signaling motifs conserved
among the Eph receptors, including the two tyrosine residues
in the juxtamembrane region that are the major phosphorylation sites in kinase-active Eph receptors, the sterile ␣ motif
(SAM) domain, and the carboxyl-terminal PDZ domain-binding
motif. Indeed, it has been shown that the PDZ domain of the
Ras-binding protein AF6 can interact with the carboxyl-terminal of EphB6 (60, 61). In addition, a protooncogene product
c-Cbl can constitutively associate with the EphB6 receptor (30,
32), and cross-linking of EphB6 in Jurkat cells results in Cbl
dephosphorylation and dissociation from Src homology 2 domain-containing tyrosine phosphatase-1 (32).
Our results that an Src family kinase associates with and
tyrosine phosphorylates EphB6 have added further evidence
that the cytoplasmic domain of EphB6 can mediate signaling.
Although Src family members have been reported to associate
with kinase-active Eph receptors (42, 44, 45, 50, 62– 64), their
association is preceded by receptor autophosphorylation and is
largely dependent on intrinsic kinase activity of the receptor.
When the receptor kinase activity is impaired, the interactions
between Eph receptors and Src family kinases are significantly
reduced (62, 63). Our results are therefore in striking contrast
to the previous results on kinase-active Eph receptors, because
the association of the EphB6 receptor with an Src family kinase
is independent of phosphorylation or kinase activity of the
receptor, and ligand stimulation induces phosphorylation of an
Src family kinase, which in turn phosphorylates EphB6. Further studies will be needed to determine the mode of their
molecular interaction and downstream signaling mechanisms
of EphB6.
Third, the extracellular domain of EphB6 may interact
with other transmembrane molecules, which mediate intracellular signaling that regulates cell adhesion and migration.
Our observations that the EphB6⌬C receptor can still promote cell migration could be explained by this mechanism.
Although molecules that interact with the EphB6 extracellular domain have not been identified, it is of particular interest that the extracellular domain of Eph receptors has been
shown to interact with the N-methyl-D-aspartate receptor
(65) and Ryk (16, 66). More investigations, including identification of molecules that directly associate with EphB6 and
downstream signaling pathways, will be required to determine molecular mechanisms by which this receptor exerts
multiple cellular functions.
Catalytically Active and Inactive Receptor Tyrosine Kinases—To date, a relatively small number of receptor tyrosine
kinases have been found to have a catalytically inactive kinase
domain. However, inactive receptor tyrosine kinases have been
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